S&P Global Inc. Common Stock (SPGI)

Teva's turnaround is real -- and may not be over.

This top Wall Street firm is convinced about UnitedHealth's prospects. Is it right?

The world is facing a growing oil supply shortfall.

The world is currently facing a serious oil supply shortage due to the closure of the Strait of Hormuz.

Volatility in the first quarter was not a bad thing for S&P Global.

S&P Global’s first-quarter performance received a positive response from the market, driven by growth in both Ratings and Indices, along with robust demand f...

Analysts think that steep pullbacks present excellent buying opportunities for these stocks.

A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.

Analysts think this top cannabis stock could more than double -- in only 12 months.

Financial intelligence company S&P Global (NYSE:SPGI) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 10.4% year on year ...

S&P Global (SPGI) Q3 2025 Earnings Transcript

S&P Global SPGI Q2 2025 Earnings Transcript

S&P Global (SPGI) Q1 2026 Earnings Transcript

Financial intelligence company S&P Global (NYSE:SPGI) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 10.4% year on year...

Financial intelligence company S&P Global (NYSE:SPGI) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 3.7% year on year to $3.92 billion...

These stocks are great bets to profit from the next big AI advances.

Financial intelligence company S&P Global (NYSE:SPGI) will be reporting results this Tuesday before the bell. Here’s what to look for. S&P Global met analyst...

Prior preparations can make black swan events less painful.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

This once-beaten-down pharma stock remains an intriguing turnaround story.

This high-flying oil stock now has a high forward earnings multiple.

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the financial exchanges & data industry, i...